| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5747 | 2021 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ... The Lancet 396 (10249), 467-478, 2020 | 2951 | 2020 |
| Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ... The Lancet 396 (10267), 1979-1993, 2020 | 1793 | 2020 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1423 | 2021 |
| Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial PD White, KA Goldsmith, AL Johnson, L Potts, R Walwyn, JC DeCesare, ... The Lancet 377 (9768), 823-836, 2011 | 1162 | 2011 |
| SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses W Dejnirattisai, J Huo, D Zhou, J Zahradník, P Supasa, C Liu, ... Cell 185 (3), 467-484. e15, 2022 | 1008 | 2022 |
| Oral versus intravenous antibiotics for bone and joint infection HK Li, I Rombach, R Zambellas, AS Walker, MA McNally, BL Atkins, ... New England Journal of Medicine 380 (5), 425-436, 2019 | 804 | 2019 |
| Expression of c-erbB-2 Oncoprotein: A Prognostic Indicator in Human Breast Cancer C Wright, B Angus, S Nicholson, JRC Sainsbury, J Cairns, WJ Gullick, ... Cancer research 49 (8), 2087-2090, 1989 | 799 | 1989 |
| Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial KRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus, S Bibi, B Blane, ... The Lancet 397 (10282), 1351-1362, 2021 | 782 | 2021 |
| Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge B Raman, MP Cassar, EM Tunnicliffe, N Filippini, L Griffanti, ... EClinicalMedicine 31, 2021 | 735 | 2021 |
| T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial KJ Ewer, JR Barrett, S Belij-Rammerstorfer, H Sharpe, R Makinson, ... Nature medicine 27 (2), 270-278, 2021 | 642 | 2021 |
| Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer C Wright, S Nicholson, B Angus, JRC Sainsbury, J Farndon, J Cairns, ... British journal of cancer 65 (1), 118-121, 1992 | 513 | 1992 |
| Expression of the antimetastatic gene nm23 in human breast cancer: an association with good prognosis C Hennessy, JA Henry, FEB May, BR Westley, B Angus, TWJ Lennard JNCI: Journal of the National Cancer Institute 83 (4), 281-285, 1991 | 498 | 1991 |
| One hundred and twelve infected arthroplasties treated with ‘DAIR’(debridement, antibiotics and implant retention): antibiotic duration and outcome I Byren, P Bejon, BL Atkins, B Angus, S Masters, P McLardy-Smith, ... Journal of antimicrobial chemotherapy 63 (6), 1264-1271, 2009 | 494 | 2009 |
| Safety and immunogenicity of novel adenovirus type 26–and modified vaccinia ankara–vectored ebola vaccines: a randomized clinical trial ID Milligan, MM Gibani, R Sewell, EA Clutterbuck, D Campbell, E Plested, ... Jama 315 (15), 1610-1623, 2016 | 403 | 2016 |
| Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses JR Barrett, S Belij-Rammerstorfer, C Dold, KJ Ewer, PM Folegatti, ... Nature medicine 27 (2), 279-288, 2021 | 363 | 2021 |
| Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre … CD Russell, CJ Fairfield, TM Drake, L Turtle, RA Seaton, DG Wootton, ... The Lancet Microbe 2 (8), e354-e365, 2021 | 341 | 2021 |
| Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a … C Jin, MM Gibani, M Moore, HB Juel, E Jones, J Meiring, V Harris, ... The Lancet 390 (10111), 2472-2480, 2017 | 334 | 2017 |
| Red blood cell deformability as a predictor of anemia in severe falciparum malaria. AM Dondorp, BJ Angus, K Chotivanich, K Silamut, R Ruangveerayuth, ... The American journal of tropical medicine and hygiene 60 (5), 733-737, 1999 | 328 | 1999 |
| Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells EA Clutterbuck, R Lazarus, LM Yu, J Bowman, EAL Bateman, L Diggle, ... Journal of Infectious Diseases 205 (9), 1408-1416, 2012 | 319 | 2012 |
